CONSIDER SELL SHORT MRNA (MDRNA)
We are short from $3.51 in pre market as our analysis does not justify the share price appreciation from the approval of generic calcitonin-salmon nasal spray for the treatment of osteoporosis www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY